| Days with a bowel movement — BB-12, 1 billion CFU | The number of days with a bowel movement per week increased by 1.54 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.39 days per week in favor of the supplement (p=0.0002). | 2/4 LowConfidence is low. The finding concerns a small change in bowel movement frequency over four weeks. Eliminating all causes of infrequent bowel movements is outside its scope. This was an additional outcome in a large trial. The trial did not demonstrate an advantage on its prespecified primary response criterion. | 1randomized trialEffect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗ | Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. 343 received this dose and 453 received placebo. | - Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗
|
|---|
| Days with a bowel movement — BB-12, 10 billion CFU | The number of days with a bowel movement per week increased by 1.30 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.15 days per week, with no clear benefit at that time point (p=0.087). | 2/4 LowConfidence is low. The finding concerns a small change in bowel movement frequency over four weeks. Eliminating all causes of infrequent bowel movements is outside its scope. The difference was more pronounced in weeks one and two. At week four, no clear advantage over placebo was observed. This was an additional outcome in the same trial. | 1randomized trialEffect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗ | Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. 452 received this dose and 453 received placebo. | - Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗
|
|---|
| More days with a bowel movement in at least two of four weeks — BB-12 | More days with a bowel movement than at baseline in at least two of the four weeks were reported by 82.9% of participants taking BB-12 and 78.7% taking placebo. There was no clear difference on this prespecified criterion (odds ratio 1.31, 95% CI 0.98–1.75). | 3/4 ModerateConfidence is moderate. The trial was large, used a prespecified criterion and analyzed participants according to their original group assignments. The result does not establish that the effects were the same. The confidence interval allows for a small benefit. The two doses were pooled in this analysis. | 1randomized trialEffect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗ | Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. There were 1,248 participants, and the two BB-12 groups were pooled. | - Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗
|
|---|
| Complete spontaneous bowel movements — HN019 | The weekly number of spontaneous bowel movements with a feeling of complete evacuation increased by 0.80 with HN019 and by 0.66 with placebo. The difference was 0.14 per week (95% CI −0.17 to 0.45, p=0.37). The trial did not demonstrate an advantage for the supplement. | 3/4 ModerateConfidence is moderate. The trial was well conducted, and 228 of 229 participants completed the treatment period. The changes shown are adjusted using a statistical model. The confidence interval allows for a small effect in either direction and does not establish an advantage for HN019 over placebo. | 1randomized trialEight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial ↗ | 229 adults aged 18–70 years with functional constipation. 112 received HN019 and 117 received placebo. 85% were women. | - Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial ↗
|
|---|
| Relief of abdominal discomfort — BB-12 | Relief in at least two of the four weeks was reported by 70.3% of participants taking 1 billion CFU, 67.1% taking 10 billion CFU and 68.1% taking placebo. Neither dose showed a clear benefit for overall abdominal discomfort. | 2/4 LowConfidence is low. Participants assessed how they felt by answering a weekly question, and relief was common with placebo as well. This outcome measures overall discomfort separately from the number of days with a bowel movement. The data for 13 participants were insufficient to determine whether they met this response criterion. | 1randomized trialEffect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗ | Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. There were 1,248 participants across three groups. | - Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗
|
|---|
| Abdominal pain in IBS — UABla-12 | Abdominal pain decreased by 1.56 points with UABla-12 and by 0.85 with placebo on a 0–10 scale. The difference was 0.71 points in favor of the supplement (p=0.001). | 2/4 LowConfidence is low. The finding comes from one study and applies specifically to pain in people with IBS. It does not extend to general discomfort in healthy people. Before group assignment, the study excluded people whose pain had already improved noticeably during a placebo run-in. This limits how well the result applies to typical consumers. | 1randomized trialLactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial ↗ | Adults aged 18–70 years with irritable bowel syndrome (IBS) in India. Of 336 people assigned to groups, 330 were included in the analysis. 110 received UABla-12 and 109 received placebo. | - Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial ↗
|
|---|
| Diarrhea during antibiotic treatment in children — BB-12 yogurt | Diarrhea occurred in 3 of 125 children in the BB-12 group and in 2 of 130 children in the group without BB-12 (p = 0.62). Diarrhea was defined as at least three loose stools per day for two consecutive days. The trial did not demonstrate an advantage from adding BB-12. | 2/4 LowConfidence is low. There were only five cases of diarrhea, so the estimated difference is imprecise. The trial compared two yogurts during prescribed antibiotic treatment. The result cannot be assumed to apply to every preparation, strain or age group. | 1randomized trialProbiotic intervention not beneficial to prevent antibiotic-associated diarrhea in absence of antibiotic-induced microbiome disruption ↗ | 255 children aged 3–12 years with an acute respiratory tract infection who were prescribed an antibiotic. 125 received BB-12 and 130 were in the control group. Most received amoxicillin. | - Probiotic intervention not beneficial to prevent antibiotic-associated diarrhea in absence of antibiotic-induced microbiome disruption ↗
|
|---|
| Fat mass — IDCC 4301 | Fat mass decreased by 0.45 kg with IDCC 4301 and by 0.16 kg with placebo, a 0.29 kg greater reduction with the supplement (p=0.0407). This measures a change in fat mass and does not imply an equal difference in total body weight. | 2/4 LowConfidence is low. The small difference was found in one study, mainly in middle-aged women. The analysis accounted for menopause, physical activity, diet and adherence. The reported final count of female participants contains an error. The group sizes shown here come from the results table. | 1randomized trialBifidobacterium lactis IDCC 4301 (B. lactis Fit™) supplementation effects on body fat, serum triglyceride, and adipokine ratio in obese women: a randomized clinical trial ↗ | Women aged 20–65 years in South Korea with a BMI of 25–30. The article reports 99 participants. The results table lists 46 in the probiotic group and 47 in the placebo group. | - Bifidobacterium lactis IDCC 4301 (B. lactis Fit™) supplementation effects on body fat, serum triglyceride, and adipokine ratio in obese women: a randomized clinical trial ↗
|
|---|
| Visceral fat — GCL2505 | Visceral fat area on a CT slice decreased by 5.1 cm² with GCL2505 and increased by 1.5 cm² with placebo. The difference was 6.6 cm² in favor of the study product. This measures area and does not indicate how many kilograms were lost. | 2/4 LowConfidence is low. The result comes from one study of a specific dairy product. Of 160 participants, 137 were included in the analysis. Most exclusions were related to scan quality. The area on a single slice does not measure total fat volume or weight change. | 1randomized trialEffect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial ↗ | 160 Japanese adults aged 20–65 years with a BMI of 23–30 were assigned to groups. The analysis included 137 participants, 69 receiving GCL2505 and 68 receiving placebo. | - Effect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial ↗
|
|---|
| Fat mass in the primary analysis — B420 | In the primary analysis, B420 alone showed no clear difference from placebo in fat mass change (p=0.76). The analysis used the original group assignments and the last available measurements for participants who dropped out. | 2/4 LowConfidence is low. Many participants did not meet all the treatment requirements, and earlier measurements were used for some missing values. Neither the positive results from additional analyses of participants who followed the protocol nor the data on the blend containing polydextrose supersede this finding for B420 alone. | 1randomized trialProbiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial ↗ | 225 adults aged 18–65 years with a BMI of 28–34.9 were assigned to four groups, and 209 were included in the overall analysis. The fat mass comparison used data from 47 people in the B420 group and 53 in the placebo group. | - Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial ↗
|
|---|
| Severity of sleep problems — BLa80 | After eight weeks, the Insomnia Severity Index (ISI) score was 2.6 points with BLa80 and 3.5 with placebo. There was no clear difference (p=0.211). A lower score indicates less severe sleep problems. | 1/4 Very lowConfidence is very low. The article text and captions disagree on participant counts and how the results are described. The figures shown here come from the allocation diagram and the ISI table. Sleep was assessed using participant responses. This questionnaire result does not establish that BLa80 prevents or treats insomnia. | 1randomized trialA double blinded randomized placebo trial of Bifidobacterium animalis subsp. lactis BLa80 on sleep quality and gut microbiota in healthy adults ↗ | According to the study flow diagram, 106 adults were assigned equally to the two groups. 52 in the BLa80 group and 49 in the placebo group completed the study. The average age was about 20 years, and participants reported sleep problems before treatment. | - A double blinded randomized placebo trial of Bifidobacterium animalis subsp. lactis BLa80 on sleep quality and gut microbiota in healthy adults ↗
|
|---|
| Eczema severity in infants — CNCM I-3446 | Eczema severity on the SCORAD scale fell from 25.9 to 12.8 points with B. lactis and from 26.9 to 11.8 with placebo. The comparison across the three groups did not show an advantage for the supplement (p=0.7). | 2/4 LowConfidence is low. This was one trial in infants with existing eczema. All groups received usual care and a special formula. This regimen is not intended for choosing a formula or dose for a child on your own. The result applies to eczema severity under the specified conditions. | 2publications reporting on one randomized trialTreatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years ↗ | 137 infants aged 3–6 months with eczema were assigned to three groups. 45 received B. lactis and 47 received placebo. All received usual topical care and an extensively hydrolyzed whey protein formula. | - Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years ↗
- Probiotics for treating eczema ↗
|
|---|